ECSS
TEVA icon

Eurizon Capital SGR SpA’s Teva Pharmaceuticals TEVA Stock Holding History

Eurizon Capital SGR SpA’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Sell
58,799
-15,092
-20% -$503K 0.01% 534
2026
Q1 		$2.22M Buy
73,891
+47,890
+184% +$1.54M 0.01% 517
2025
Q4 		$812K Buy
+26,001
New +$641K ﹤0.01% 543

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Eurizon Capital SGR SpA's TEVA Position: Q2 2026 in Review

Eurizon Capital SGR SpA reduced its Teva Pharmaceuticals (TEVA) stake by 20% in Q2 2026, selling an estimated $503K and leaving 58,799 shares worth $1.99M. The position accounts for 0.01% of the portfolio, ranked #534.

Eurizon Capital SGR SpA first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.22M in Q1 2026. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Eurizon Capital SGR SpA held 58,799 shares of Teva Pharmaceuticals worth $1.99M as of Q2 2026.
  • Eurizon Capital SGR SpA sold 15,092 Teva Pharmaceuticals shares in Q2 2026, an estimated $503K.
  • Teva Pharmaceuticals made up 0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #534 holding.
  • Eurizon Capital SGR SpA first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Eurizon Capital SGR SpA's Teva Pharmaceuticals position peaked at $2.22M in Q1 2026.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.